Chemed's Q1 2026: VITAS Shines, Roto-Rooter Faces Challenges

Chemed Corporations first quarter 2026 earnings exceeded expectations with a 1.6% increase in revenue to $657.5 million, beating analyst forecasts by 1.2%. Adjusted earnings per share of $5.65 surpassed estimates by 6.6%, and adjusted EBITDA reached $116.3 million. VITAS, their hospice division, drove growth with a 6.9% rise in admissions, despite running fewer full-time staff and maintaining margins. Roto-Rooter saw early residential revenue growth but faced sales losses due to weather storms. Chemed plans to add 60 full-time equivalents at VITAS and manage costs at Roto-Rooter to maintain momentum. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/099226e738911bcc